Vixotrigine
Clinical data
Other namesRaxatrigine; CNV1014802; GSK-1014802; BIIB 074
Routes of
administration		By mouth
ATC code
  • None
Identifiers
  • (2S,5R)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC18H19FN2O2
Molar mass314.360 g·mol−1
3D model (JSmol)
  • C1CC(NC1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N
  • InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1
  • Key:JESCETIFNOFKEU-SJORKVTESA-N

Vixotrigine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), formerly known as raxatrigine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).[1][2][3] Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain.[4] It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.[4]

See also

References

  1. ↑ "CNV1014802". Convergence Pharmaceuticals.
  2. ↑ McMahon S, Koltzenburg M, Tracey I, Turk DC (1 March 2013). Wall & Melzack's Textbook of Pain: Expert Consult - Online. Elsevier Health Sciences. p. 508. ISBN 978-0-7020-5374-0.
  3. ↑ Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
  4. 1 2 "Vixotrigine - Biogen". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.